louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02701699: 18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer
Official title: A Feasibility Study of Hypoxia Imaging in Patients With Lung Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Lung Cancer
Keywords: Lung Cancer
FAZA PET Imaging
Lung Radiotherapy
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2016-03-08
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to look for low levels of oxygen (hypoxia) in lung cancer using a positron emission tomography (PET) scan. Hypoxia can influence how lung cancer grows and responds to treatments like radiotherapy and chemotherapy. The use of PET scans to measure hypoxia may be better and simpler than the approaches used previously. This study will assess whether or not PET scans can provide useful information about hypoxia in lung cancer.

In this study, a radiotracer called Fluoroazomycin Arabinoside (FAZA) will be used to measure hypoxia in the patient's tumour. FAZA has already been used in many cancers including lung cancer. Patients who consent to participate in this trial will receive 1 FAZA PET Scan prior to their first radiotherapy treatment


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years
2. Patients with stage II or III lung cancer (both NSCLC and SCLC) qualifying for radiotherapy to the primary tumor, with or without treatment of mediastinal or hilar lymph nodes
3. Intention to treat using radiotherapy according to the current treatment policies of the PMH Lung Group
4. Concurrent systemic therapy allowed
5. A negative serum pregnancy test within the two week interval immediately prior to PET-CT imaging, in women of child-bearing age
6. Ability to provide written informed consent to participate in the study

Exclusion Criteria:

1. Previous radiotherapy to intended treatment volumes.
2. Previous systemic therapy
3. Active malignancy other than lung cancer
4. Unable to remain supine for more than 60 minutes
5. Pregnancy
6. Age less than 18 years old
7. Failure to provide written informed consent

Primary outcomes:
measure: Number of patients with lung cancer using the PET tracer FAZA to image primary tumor hypoxia prior to treatment with radiotherapy
timeFrame: 5 years
measure: Number of patients with lung cancer using 4D (gated) and static PET imaging of FAZA uptake
timeFrame: 5 years
Secondary outcomes:
measure: Proportion of the volume of injected FAZA tracer taken up in the tumor prior to treatment with radiotherapy
timeFrame: 5 years
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network, Princess Margaret Cancer Centre
state: Ontario
Study officials:
affiliation: The Princess Margaret Cancer Foundation
name: Alex Sun, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01430299: Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion
Official title: Efficacy and Safety of Integra Accell Evo3 Demineralized Bone Matrix Instrumented Posterolateral Lumbar Spine Fusion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stenosis
Spondylosis
Degenerative Changes
Lead sponsor: SeaSpine, Inc.
Sponsor class: INDUSTRY
First posted: 2011-09-08
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for posterolateral spine fusion with a retrospective comparison to a historical patient cohort.

Detailed description: The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for posterolateral spine fusion with a retrospective comparison to a historical patient cohort. The historical patient cohort has not been previously published and therefore, no reference to this group can be provided.

Eligibility criteria: Inclusion Criteria:

* Age 18 years of age or older at the time of surgery
* Require spinal fusion using posterior Transforaminal Lumbar Interbody Fusion (TLIF), Posterolateral Fusion (PLF) or Posterior Lumber Interbody Fusion (PLIF) in 1 to 3 levels between L3-S1
* Follow-up radiographic imaging post surgery

Exclusion Criteria:

* Long term users of medications known to inhibit fusion,bone metabolism or epidural steroid injections
* Immunosuppressive agents, Disease Modifying Anti-rheumatic drugs (DMARDs) or any similar immunomodulating drugs, Growth Factors or Insulin
* Treated with radiotherapy since their surgery
* Medical conditions known to impact bone metabolism, such as Paget's disease, osteoporosis
* Pregnant or lactating women or women wishing to become pregnant
* Prisoner
* Participating in an investigational drug or another device study

Primary outcomes:
measure: Number of Radiographic Assessments That Indicate Posterolateral Fusion at 12 Months Post Surgery
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of CA-Davis, Dept. of Orthopaedics, Adult & Pediatric Spine Surgery
state: California
Study officials:
affiliation: University of CA - Davis
name: Eric Klineberg, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02426099: Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension
Official title: Prevalence and Treatment of Resistant Hypertension in Diabetic Patients in Yaounde
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension, Resistant to Conventional Therapy
Diabetes Mellitus
Keywords: Resistant hypertension
diabetes mellitus
Spironolactone
African
Lead sponsor: Yaounde Central Hospital
Sponsor class: OTHER_GOV
Collaborators: name: University of Yaounde 1
First posted: 2015-04-24
Enrollment: 17
Sex: ALL
Minimum age (years): 21
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a four-week randomized controlled single blinded trial of subjects presenting with resistant hypertension in a specialized diabetes care unit of Cameroon. They are randomly assigned using the method of blocks to treatment with a daily 25mg of spironolactone or to routine intensification of antihypertensive regimen , all added to previous regimen with unchanged diet. Visits are scheduled at the start of the treatment, at weeks two and four following add-on therapy initiation. The primary outcome is change in office and self-measurement blood pressure recorded at each visit, and secondary outcomes are variations in serum potassium, sodium, and creatinine levels.


Eligibility criteria: Inclusion Criteria:

* Resistant hypertension
* Diabetes mellitus

Exclusion Criteria:

* T2DM with overt acute/chronic complications,
* serum potassium ≥ 5.5 mmol/l,
* estimated Glomerular Filtration Rate (eGFR) calculated using the Modification of Diet in Renal Disease formula ≤ 30 ml/min/1.73m² of body weight,
* absolute contraindication to any of the drug regimen of the trial,
* and current aldosterone antagonist treatment or cessation within the last 15 months

Primary outcomes:
measure: Efficacy (Blood pressure reduction)
timeFrame: 4 weeks
Secondary outcomes:
measure: Potassium (Change in serum potassium)
timeFrame: 4 weeks
measure: Creatinine (Change in serum creatinine)
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Yaounde
country: Cameroon
facility: National Obesity Centre, Yaounde Central Hospital
state: Centre
Study officials:
affiliation: University of Yaounde 1
name: Jean-Claude Mbanya, MD, PhD
role: STUDY_CHAIR
References:
citation: Djoumessi RN, Noubiap JJ, Kaze FF, Essouma M, Menanga AP, Kengne AP, Mbanya JC, Sobngwi E. Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population. BMC Res Notes. 2016 Mar 23;9:187. doi: 10.1186/s13104-016-1987-5.
Clinical trial NCT03034499: Single Versus Multi-port Robotic Assisted Sacrocolpopexy for Repair of Vaginal Apex Prolapse
Official title: Single Versus Multi-port Robotic Assisted Sacrocolpopexy for Repair of Vaginal Apex Prolapse
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pelvic Organ Prolapse
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2017-01-27
Enrollment: 80
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A prospective randomized controlled study intended to compare the efficacy of 2 methods of robotic assisted sacrocolpopexy for the repair of vaginal apex prolapse:

1. Via single-port.
2. Via multi-port.

Detailed description: One hundred female patients diagnosed with vaginal apex prolapse will be recruited to a prospective randomized controlled study intended to compare the efficacy of 2 methods of robotic assisted sacrocolpopexy:

1. Via single-port.
2. Via multi-port. The patients will be evaluated and randomized 2 weeks before the expected date of surgery during which eligibility will be examined.

Patients' electronic files will be reviewed post operatively to acquire information regarding medical history, prolapse scores, surgical information, anesthesia information and surgical complications.

Patients will have 3 week and 3 month post operative follow-up sessions to determine surgical success, late complications and patient satisfaction.

Eligibility criteria: Inclusion Criteria:

* Female patients with vaginal apex prolapse that are eligible for repair by sacrocolpopexy.

Exclusion Criteria:

* Patients after previous hysterectomy.
* Patients after previous surgical procedures for prolapse repair.

Primary outcomes:
measure: Comparison of surgical time
timeFrame: Up to four months (2 weeks before surgery until 3 months post-surgery).
Secondary outcomes:
measure: Comparison of surgical success
timeFrame: Up to four months (2 weeks before surgery until 3 months post-surgery).
measure: Comparison of surgical complications
timeFrame: Up to four months (2 weeks before surgery until 3 months post-surgery).
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam health care campus
Study officials:
affiliation: Rambam Health Care Campus
name: Roy Lauterbach, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Matanes E, Boulus S, Lauterbach R, Amit A, Weiner Z, Lowenstein L. Robotic laparoendoscopic single-site compared with robotic multi-port sacrocolpopexy for apical compartment prolapse. Am J Obstet Gynecol. 2020 Apr;222(4):358.e1-358.e11. doi: 10.1016/j.ajog.2019.09.048. Epub 2019 Oct 4.
Clinical trial NCT05739799: To Comapre The Effectiveness of Two Lasers in The Treamment of Unwanted Hair
Official title: Compariosn of Effectiveness of Diode Laser System Versus Intense Pulse Light (IPL) in The Treatment of Unwanted Hair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hirsuitism
Lead sponsor: Combined Military Hospital Abbottabad
Sponsor class: OTHER
First posted: 2023-02-22
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: A total of 60 female patients (30 patients in each group) with unwanted facial hair diagnosed by a consultant dermatologist were included in this study. In Group A patients were subjected to intense pulse light therapy while patients in Group B were subjected to diode laser for three sessions one month apart. Effectiveness in both groups was ascertained in terms of hair reduction, less adverse effects, side effects and patients' satisfactory response at the end of final session.


Eligibility criteria: Inclusion Criteria:

* Female patients with hirsuitism were included in the study.

Exclusion Criteria:

* tendency to develop hypertrophic scarring/keloid,
* underwent any treatment for unwanted facial hair in last two years
* pregnant/lactating women
* with hormonal imbalance and PCOS were also not in included in the study.

Primary outcomes:
measure: Effectiveness of diode and IPL laser in hirsuitism
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Abbottābād
country: Pakistan
facility: Sara Ilyas
state: Kpk
Study officials:
References:
Clinical trial NCT03087799: Brief Behavioral Treatment for Sleep Problems in IBS Study
Official title: Brief Behavioral Treatment for Sleep Problems in Irritable Bowel Syndrome: a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Irritable Bowel Syndrome
Sleep Disturbance
Lead sponsor: Beth Israel Deaconess Medical Center
Sponsor class: OTHER
First posted: 2017-03-23
Enrollment: 25
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with Irritable Bowel Syndrome (IBS) often report more fatigue and sleep disturbances compared to their healthy counterparts and compared to patients with other GI disorders. This pilot study will evaluate the feasibility of a Brief Behavioral Treatment for Insomnia (BBT-I) in Irritable Bowel Syndrome. 40 participants will be recruited; 20 will receive 4 weeks of BBT and 20 will be assigned to a wait list control group (WLC). The primary aim of the current project is to assess feasibility of administering BBT-I to a sample of patients with IBS. Because behavioral sleep treatment has not yet been studied in IBS or any other GI population, this project will provide information about treatment adherence, recruitment, and effect sizes. Secondary aims include evaluating the impact of BBT-I on sleep quality and IBS symptom severity.


Eligibility criteria: Inclusion Criteria:

* Age 20-50
* Meet diagnostic criteria for IBS
* Stable medication for IBS for at least 1 month
* Stable medication for sleep for at least 1 month
* ISI cutoff score of 10 or higher
* Completes at least 5 out of 7 days of daily symptom and sleep diary during 1 week baseline

Exclusion Criteria:

* Medical history of significant head injury or other neurological disorder
* Pregnancy (self-reported)
* Post-menopause
* Major concomitant medical conditions
* Major psychiatric diagnosis with comorbid sleep problems
* Taking medications that might interfere with sleep
* Confirmed or suspected other untreated sleep disorder
* Active illicit drug use

Primary outcomes:
measure: Change in Irritable Bowel Syndrome Severity Scoring System
timeFrame: 5 weeks
Secondary outcomes:
measure: Change in Insomnia Severity Index
timeFrame: 5 weeks
measure: Change in Pittsburgh Sleep Quality Index
timeFrame: 5 weeks
Other outcomes:
Locations:
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
Study officials:
References:
Clinical trial NCT06470542: Two-level ESPB in Total Knee Arthroplasty
Official title: Two-level Vs One-level Erector Spinae Plane Block in Total Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Knee Osteoarthritis
Knee Pain Chronic
Knee Arthritis
Lead sponsor: Poznan University of Medical Sciences
Sponsor class: OTHER
First posted: 2024-06-24
Enrollment: 60
Sex: ALL
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Effect of two-level ESPB in Total Knee Arthroplasty

Detailed description: Knee arthroplasty is one of the most common orthopaedic procedures, especially in elderly patients, due to the deformation of joints. Patients may complain of severe pain due to surgical trauma and prostheses. Regional anaesthesia methods may be performed to reduce the inflammatory response, opioid consumption, and opioid-related side effects.

Eligibility criteria: Inclusion Criteria:

* patients scheduled for total hip arthroplasty
* patients aged \>65 and \<100 years
* patients able to provide informed consent
* patients able to reliably report symptoms to the research team

Exclusion Criteria:

* inability to provide first-party consent due to cognitive impairment or a language barrier

Primary outcomes:
measure: Total Opioid Consumption
timeFrame: 48 hours after surgery
Secondary outcomes:
measure: Time to first rescue opioid analgesia
timeFrame: 48 hours after surgery
measure: Numerical Rating Scale [range 0:10]
timeFrame: 8 hours after surgery
measure: Numerical Rating Scale [range 0:10]
timeFrame: 12 hours after surgery
measure: Numerical Rating Scale [range 0:10]
timeFrame: 24 hours after surgery
measure: Numerical Rating Scale [range 0:10]
timeFrame: 48 hours after surgery
measure: NLR
timeFrame: 24 hours after surgery
measure: NLR
timeFrame: 48 hours after surgery
measure: PLR
timeFrame: 24 hours after surgery
measure: PLR
timeFrame: 48 hours after surgery
measure: Quadriceps muscle strength assessed using medical research council scale [range 0:5]
timeFrame: 4 hours after surgery
measure: Quadriceps muscle strength assessed using medical research council scale [range 0:5]
timeFrame: 8 hours after surgery
measure: Quadriceps muscle strength assessed using medical research council scale [range 0:5]
timeFrame: 12 hours after surgery
measure: Quadriceps muscle strength assessed using medical research council scale [range 0:5]
timeFrame: 24 hours after surgery
measure: Quadriceps muscle strength assessed using medical research council scale [range 0:5]
timeFrame: 48 hours after surgery
Other outcomes:
Locations:
city: Poznan
country: Poland
facility: Poznan University of Medical Sciences
state: Poznań
Study officials:
affiliation: Poznań University of Medical Sciences
name: Malgorzata Domagalska, M.D. Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT02541942: Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Official title: Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2015-09-04
Enrollment: 19
Sex: MALE
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study is conducted globally. This study describes pharmacogenetic testing of saliva samples from patients who participated in the NN1731-3562 trial (adept™2) (NCT01392547). The objective is to determine the HLA (human leukocyte antigen) type and polymorphisms in the FVII gene in patients previously exposed to rFVIIa analogue.


Eligibility criteria: Inclusion Criteria:

* Informed consent obtained before collection of saliva samples
* Previous participation in adept™2 trial with 5 or more exposure days to rFVIIa analogue

Primary outcomes:
measure: Determination of HLA Type
timeFrame: Up to 12 months
measure: Determination of Polymorphisms in the FVII Gene
timeFrame: Up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Novo Nordisk Investigational Site
state: Arizona
city: Tampa
country: United States
facility: Novo Nordisk Investigational Site
state: Florida
city: Atlanta
country: United States
facility: Novo Nordisk Investigational Site
state: Georgia
city: Iowa City
country: United States
facility: Novo Nordisk Investigational Site
state: Iowa
city: Boston
country: United States
facility: Novo Nordisk Investigational Site
state: Massachusetts
city: Athens
country: Greece
facility: Novo Nordisk Investigational Site
city: Thessaloniki
country: Greece
facility: Novo Nordisk Investigational Site
city: Kashihara-shi, Nara
country: Japan
facility: Novo Nordisk Investigational Site
city: Shinjuku-ku, Tokyo
country: Japan
facility: Novo Nordisk Investigational Site
city: Suginami-ku, Tokyo
country: Japan
facility: Novo Nordisk Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: Novo Nordisk Investigational Site
city: Timisoara
country: Romania
facility: Novo Nordisk Investigational Site
state: Timis
city: Belgrade
country: Serbia
facility: Novo Nordisk Investigational Site
city: Novi Sad
country: Serbia
facility: Novo Nordisk Investigational Site
city: Bangkok
country: Thailand
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
Clinical trial NCT05797142: Virtual Reality-Based Relaxation Program on Pain Intensity, Anxiety Level in Patients to be Applied With Endoscopy
Official title: The Effect of Virtual Reality-Based Relaxation Program on Pain Intensity, Anxiety Level and Patient Satisfaction in Patients to be Applied With Endoscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety
Pain
Keywords: virtual reality glasses
Pain
Anxiety
Endoscopy
Lead sponsor: Istanbul Sabahattin Zaim University
Sponsor class: OTHER
First posted: 2023-04-04
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is an experimental study with pre-test and post-test control groups
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study was conducted to evaluate the effect of relaxation exercise with VR (Virtual Reality) glasses on pain severity, anxiety level, physiological symptoms of anxiety and satisfaction in patients undergoing endoscopy.

Detailed description: Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses.

Eligibility criteria: Inclusion Criteria:

* Being over 18 years old
* Ability to communicate adequately
* Absence of psychiatric problems
* Volunteering to participate in the research

Exclusion Criteria:

Those who have communication problems

* Those with psychiatric problems
* Being unconscious

Primary outcomes:
measure: Visual Analog Scale
timeFrame: Baseline (Before endoscopy)
measure: Visual Analog Scale
timeFrame: 5 minute after endoscopy
Secondary outcomes:
measure: Anxiety Assessment Scale
timeFrame: Baseline (Before endoscopy)
measure: Anxiety Assessment Scale
timeFrame: 5 minute after endoscopy
measure: Physiological Symptoms of Anxiety Follow-up Form
timeFrame: Baseline (Before endoscopy)
measure: Physiological Symptoms of Anxiety Follow-up Form
timeFrame: 1 minute after endoscopy
measure: Virtual Reality Glasses Application Satisfaction Form
timeFrame: 5 minute after endoscopy
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Sabahattin Zaim University, Faculty of Health Sciences
state: Turkiye
Study officials:
affiliation: Istanbul Sabahattin Zaim University
name: Zülfünaz Özer, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Genc H, Korkmaz M, Akkurt A. The Effect of Virtual Reality Glasses and Stress Balls on Pain and Vital Findings During Transrectal Prostate Biopsy: A Randomized Controlled Trial. J Perianesth Nurs. 2022 Jun;37(3):344-350. doi: 10.1016/j.jopan.2021.09.006. Epub 2022 Apr 7.